Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia

Leukemia Research

Volumn 25, Issue 5, 2001, Pages 395-405

  Ferrao, Petranel ^a   Sincock, Paul ^a,b   Cole, Stephen ^a   Ashman, Leonie ^a,b  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

AML; Drug efflux; Intracellular P glycoprotein; Multidrug resistance

Indexed keywords

CYCLOSPORIN A; DAUNORUBICIN; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; VERAPAMIL;

CELL STRAIN K 562; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LEUKEMIA CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW;

EID: 0035066434     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(00)00156-9     Document Type: Article

References (73)

1. Acute myelogenous leukemia: Recent advances in therapy
2. Multiple-drug resistance in human cancer
3. Amplification of DNA sequences in human multidrug-resistant KB carcinoma cells
4. Isolation and expression of a complementary DNA that confers multidrug resistance
5. Expression of a multidrug resistance gene in human cancers
6. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation
7. Classical multidrug resistance in acute myeloid leukaemia
8. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
9. Molecular analysis of the multidrug transporter
10. The P-glycoprotein efflux pump: how does it transport drugs?
11. A retrovirus carrying and MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MCDK cells
12. Molecular mechanisms of multidrug resistance in cancer chemotherapy
13. Non-P-glycoprotein drug export mechanisms of multidrug resistance
14. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line
15. The MRP gene associated with a non-P-glycoprotein multi-drug resistance encodes a 190-kDa membrane bound protein
16. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump
17. r 11000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance
18. The drug resistance-related protein LRP is the human major vault protein
19. Vaults are up-regulated in multidrug-resistant cancer cell lines
20. Clinical relevance of drug resistance genes in malignant disease
21. The prognostic significance of the expression and function of Multidrug resistance Transporter Proteins in Acute Myeloid Leukemia: Studies of the Southwest Oncology Group Leukemia Research Program
22. Multidrug resistance in leukemia
23. MDR1 gene expression and treatment outcome in acute myeloid leukemia
24. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity
25. High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission
26. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
27. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia
28. P-glycoprotein expression on acute myeloid leukemia blast cells at diagnosis predicts response to chemotherapy and survival
29. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry
30. P-gp and MRP activities using Calcein-AM are prognostic factors in adult acute myeloid leukemia patients
31. P-glycoprotein expression and prognostic value in acute myeloid leukemia
32. Expression of the multidrug resitance-associated protein (MRP) in acute leukaemia
33. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias
34. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers
35. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia
36. Multidrug resistance-associated protein (MRP) in haematological malignancies
37. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients
38. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia
39. P-glycoprotein (P-GP) and lung resistant related protein (LRP) expression and function in leukaemic blast cells
40. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome
41. Expression of the human major vault protein LRP in acute myeloid leukemia
42. Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia
43. High levels of lung resistance protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone
44. Functional multidrug resistance phenotype associated with combined overexpression of P-gp/MDR1 and MRP together with 1-B-D-arabinofuranosylcyostine may predict clinical response in acute myeloid leukemia
45. Simultaneous activity of MRP1 and P-gp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia
46. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study
47. Drug resistance factors in acute myeloid leukemia: a comparative analysis
48. Phase I/II trial of cyclosporin as a chemotherapy-resitance modifier in acute leukemia
49. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL)
50. Mechanisms of drug resistance in hematologic malignancies
51. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia
52. Multidrug resistance and its reversal
53. Resistance to chemotherapy in acute leukemia
54. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data analysis and interpretation
55. US-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: Data reporting
56. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations
57. Multicentric evaluation of the MDR phenotype in leukemia. French Network of the Drug Resistance Intergroup, and Drug Resistance Network of Assistance Publique-Hôpitaux de Paris
58. Testing the role of P-glycoprotein expression in clinical trials: applying pharmacological principles and best methods for detection together with good clinical trials methodology
59. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy
60. Examination by laser scanning confocal fluorescence imaging microscopy of subcellular localization of anthracyclines in parent and multidrug resistant cell lines
61. Altered intracellular distribution of Daunorubicin in immature acute myeloid leukemia cells
62. Confocal scanning microspectrofluorometry reveals specific anthracycline accumulation in cytoplasmic organelles of multidrug-resistant cancer cells
63. Functional intracellular P-glycoprotein
64. Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia
65. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukaemia cell lines
66. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux- cases
67. Discordant P-glycoprotein antigen expression and transport function in acute myeloid leukemia
68. Methods to detect P-glycoprotein and implications for other drug resistance-associated proteins
69. Peanut agglutinin: a marker for normal and leukaemic cells of the monocyte lineage
70. Increased expression of c-Kit or its ligand Steel Factor is not a common feature of adult acute myeloid leukaemia
71. Pharmacologic approaches to reversing multidrug resistance
72. ATP-dependent uptake of anti-neoplastic agents by acidic organelles
73. Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells